



Prospective Study on Upper GI Bleeding

Pavani Tekumalla¹, Dr. Vamshi Krishna V. M.D,DM Gastroenterologist², Dr. Y. Karunakar Reddy M.Pharm,Ph.D³,
Roqsar Firdouse⁴

^{1,2,3,4}Department Of Pharmacy Practice, S.R.R College Of Pharmaceutical Sciences
Valbhapur (V), Elkathurthy (M), Warangal (U) Telangana, India-505476

ABSTRACT

Aims: The aim of this study to evaluate the possible aetiology of bleed & clinical profile of patients

Objectives:

- To assess the causes of the upper gastrointestinal haemorrhage.
- To assess the management of upper gastrointestinal bleeding.
- To review the complications of upper gastrointestinal haemorrhage.

Methodology: A Hospital based prospective study was carried out for 6 months at single center, Warangal, Telangana, India. Patients were enrolled in this study based upon various symptoms and were assessed. Our study was used to define the possible etiology of bleed. All the relevant and necessary data was collected from patient's care notes, Treatment charts Interviewing patient, Interviewing health care professional's patient related information collected and confidentiality maintained.

Results: A total of 200 patients were enrolled in this study in which 11-80 years age using as subjects were enrolled from single centre. According to Gender wise 200 patients were divided 136(68%) males and 64(32%) females. According to Age wise categorization of the study population majority were in the age of 41-60(61%) years followed by age group 21-40 years(35.5%),61-80 years (9.5%) and 0-20 years (8.5 %) respectively. According to symptom wise distribution majority was found to be Hematemesis 106(53%) followed by Melena 77(39%) and both 17(9%) respectively.

Conclusion: In this study we found that Endoscopy can be used as diagnostic as well as therapeutic measures, it is therefore recommended within 24 hours of bleeding.

KEY WORDS: CLD (chronic liver disease), hemorrhagic gastritis, congestive gastropathy, UGIE(upper gastrointestinal endoscopy).

INTRODUCTION

- Upper gastrointestinal bleeding (UGIB) is a potentially life threatening abdominal emergency that cause of hospitalization.
- Upper GI bleeding (UGIB) is defined as bleeding from a source proximal to the ligament of the ligament of the ligament of the Treitz.
- Acute upper gastrointestinal bleeding is characterised by :
 - Haematemesis
 - Melaena
 - Hematochezia.
- Heavy bleeding from the upper GI tract maybe associated with brighter rectal bleeding.
- Bleeding from the upper GI tract is approximately four times as common as bleeding from the lower GI tract.
- Gastrointestinal bleeding in the GI tract, which include the oesophagus, stomach, small intestine.
- Bleeding that originates above the ligament of Treitz usually present either as hematemesis or melena, bleeding that originates below most commonly present as haematochezia
- Most common cause of upper GI bleeding is gastro -oesophageal varices, Common cause of upper GI bleeding helicobacter pylori, Chronic liver disease is the quite often cause of upper GI bleeding. Some medication such as anti coagulants, platelet



inhibitors, antibiotic, NSAIDS.

- SSRI s are less cause of upper GI bleeding.
- Acute Gastrointestinal bleeds can also lead to shock which is a medical emergency.
- The chronic liver disease is most common cause of portal hypertension.

SYMPTOMS:

- Hematemesis: Vomiting of blood
- Coffee grounds: Results of gastric acid effect on blood
- Malena: Black tarry stool
- Haematochezia: Bright red blood in stools

CAUSES OF UPPER GI BLEEDING:

- Most common cause of upper GI bleeding:
 1. Duodenal ulcers
 2. Esophagitis
 3. Oesophageal varices
 4. Gastric tumours
 5. Gastritis
 6. Gastric ulcers
 7. Mallory-wise syndrome
 8. Peptic ulcer

RISK FACTORS OF UPEER GI BLEEDING:

- Age
- Previous history of gastrointestinal bleeding
- Chronic kidney disease
- Cardiovascular disease
- Cirrhosis and portal hypertension
- Helicobacter pylori infection
- Medications
- Gastroesophageal reflux disease
- Gastric acid hypersecretion.

DIAGNOSIS:

- UGIE (upper gastrointestinal endoscopy)

TREATMENT OF UPPER GASTROINTESTINAL BLEEDING:

- Esomeprazole 40 mg PO q24 h
- Lansoprazole 30 mg PO q 24 h
- Pantoprazole 40 mg PO q 24 h
- Cimetidine 37.5 to 50 mg /hr IV (900-1200mg /day)
- Ranitidine 50 mg IV q8 h (or)6.25mg/hr continuous IV infusion (150 mg / day)
- Famotidine 20 mg IV q 12 hr or 10 mg IV initially (40 mg / day)



- Treatment of oesophageal varices or other lesion caused by portal hypertension
- Octreotide 50 micro gram /hr bolus by a continuous intravenous drip at 50 micro gram/hr for 72 hrs.
- Treatment of upper GI bleeding in patient with cirrhosis:
- Ciprofloxacin 400 mg IV q 8h
- Cefepime 2g iv q 12 h
- Erythromycin 250 mg iv once 20minutes prior to endoscopy

METHODOLOGY

Study site:

The Present study was conducted at Vamshi gastro and liver clinic. (Hanmakonda, Warangal and Telangana, India).

Study design:

A hospital based Prospective observational study.

Study-Period:

The study was carried at for period of 6 months (November 2021 - May 2022)

Study-sample size:

The study was conducted on 200 patients single centre.

Study criteria:

- **Inclusion criteria:**
- Patients suffering with gastrointestinal problems.
- Patient with chronic usage of NSAIDS.
- Patient with chronic alcoholic disease.
- Patient with a known history of chronic liver disease.
- A Sedentary life style.
- 1-80years male and female patients.
- **Exclusion criteria:**
- Pregnancy women and Breastfeeding mother.

Study procedure:

- The study was initiated at single centre by selecting the patients based on inclusion criteria of the study. Patient s with age 0-100 age enrolled in our studies who were suffering with upper GI bleeding Patients were enrolled in this study based on Past medical history, Personal history (occupation, life style, locality), Causes (medication ,Diet, Disease),Diagnosis. Our study was used to evaluate the possible aetiology of bleed UGIB, Management of upper gastrointestinal bleeding.
- **Source of Data:** All relevant and necessary data was collected from
- Patient case notes,
- Patients,
- Prescriptions,
- Physicians,
- Laboratory reports,
- Patients care taker,
- **Statistical method:**
- Statistical analysis was performed using Microsoft office excel to determine average number of drugs prescribed per prescription.
- **Data collection form:**



- A suitable designed data collection form was prepared for patient who include demographic details of patient such as age, gender, address, past medical history, personal history (life style, occupation, locality) causes (diseases, medications, diet) diagnosis, current Medication chart.
- **Informed consent form:**
- A patient inform consent (annexure) form was prepared consist of description of the study the informed consent was obtained from patients who met inclusion criteria and work enrolled in the study

RESULTS

- In 6month period of study a total of 200 patient all aged group were included and were assessed.

GENDER WISE DISTRIBUTION:

S.no	Gender	Number of people
1	Male	136
2	Female	64




Fig -2 gender wise distribution

Among 200 patient s male were predominance with 136(68%) and 64 (32%) were females.

AGEWISE DISTRIBUTION:

S.no	Age	Male	Female	Total cases
1	0-20	5 (2.5%)	12 (6%)	17
2	21-40	44 (22%)	27(13.5)	71
3	41-60	74 (37%)	18 (9%)	92
4	61-80	12 (6%)	7(3.5%)	19
5	81-100	1 (0.5%)	0(0%)	1




Fig -3 age wise distribution

Among 200 patients majority were in the age of 41-60 years (46%) followed by age group 21-40 years (35.5%) and 61-80 years (9.5%) 0-20 years (8.5%) respectively.

SYMPTOMSWISE DISTRIBUTION

S.no	Symptoms	Total cases
1	Hematemesis	106(53%)
2	Malena	77(38%)
3	Both	17(9%)




Fig -4 symptoms wise distribution

Among 200 patients, majority was found to be hematemesis 106(53%) followed by melena 77 (39%) and both (hematemesis , melena)17 (9%)



DIAGNOSISWISE DISTRIBUTION:

DIAGNOSIS	NUMBER OF PEOPLE
Varices	53
Ulcers	47
Antral gastritis	16
Hemorrhagic gastritis	14
Esophagitis	34
Erosive gastritis	4
Pan gastritis	7
Duodenitis	5
Congestive gastropathy	2
Corrosive injury	4
Mallory wise syndrome	1
Ultero proliferative growth	3
Corporal gastritis	3
Necrotic ulceration	2
Fundal gastritis	4
Fundal malignancy	1




Fig -5 diagnosis wise distribution



Among 200 patient majority was found to be varices 53(26.5%), followed by ulcer s47(23.5%), esophagitis34(17%), antral gastritis 16(6%), hemorrhagic gastritis 14(7%), pan gastritis 7(3.5%), duodenitis 5(2.5%), fundal gastritis4(2%), corrosive injury 4(2%), ulceroproliferative growth 3(1.5%), erosive gastritis 4(2%), corporal gastritis 3 (1.5%), congestive gastropathy 2(1%), necrotic ulceration 2(1%), fundal gastritis1(0.5%), Mallory wise syndrome 1(0.5%).

OCCUPATIONWISE DIDTRIBUTION:

OCCUPATION	NUMBEROF PEOPLE
Driver	13
Labour	30
Farmer	35
Homemaker	40
Student	20
Software	22
None	40




Fig -6 occupation wise distribution

Among200 patients 40 patients were home makers (20%), followed by none 40 (20%) , farmer 35 (17.5%),labour 30(15%),software 22(11%),students 20 (10%), and driver 13(6.5%)respectively.



LIFESTYLE WISE DISTRIBUTION:

Lifestyle	Number of people
Alcoholic	98
Smoker	6
Both	13
Tobacco	1
None	82



Fig -7 lifestyle wise distribution

Among 200 patient majority was found to be alcoholic 98(49%) followed by smoker 6 (3%), both (alcoholic and smoker) 13 (6.5%), tobacco 1(0.5%) and none 82(41.5%).

LOCALITYWISE DISTRIBUTION:

Locality	Number of people
Urban	115
Rural	85





Fig -8 locality wise distribution

Among 200 patients 115 patients belong to rural area (57.5%) followed by 85 patients belong to urban area (42.5%).

CAUSEWISE DISTRIBUTION:

CAUSE	NUMBER OF PEOPLE
ALD	6
CLD	6
ALD-CLD	11
Medication	16
Diet	72
Ingestion of acid and Ingestion of foreign	4 1
None	84



Among 200 patient most of the patients with unknown cause were 84 (42%) followed by diet 72(36%) NSAIDS 16 (8%), ALD - CLD 11(5.5%), ALD6(3%), CLD 6(3%), Ingestion of acid 4(2%) ingestion of foreign particle 1(0.5%).

DISCUSSION

The patient study was designed to study the prospective study on upper GI bleed. Upper gastrointestinal bleed may be various causes that include varices, ulcers, growth, tears in the oesophagus etc. in the gastrointestinal tract.

In this study a hospital study of 200 patients with upper GI bleed of all ages using subjects were enrolled from a single centre.

Our study shows male predominance with 136 patients (68%) and female with 64(32%).

This results depicts that male are more prone to gastrointestinal disorder.

Our study found that incidence of gastric malignancy was higher as compared to other studies, which may be due to major risk factors in the study population such as smoking and alcohol.

Among 200 patients 98 patients were alcoholic which gave attention towards patient risk and 13 number of patients with a habit of both (alcoholic and smoker)

As per the study conducted by Brintha K. Enestvedt et al (16). The most common presenting complaint was hematemesis (43.15%) followed by melena.

In our study the most common presenting complaints were hematemesis in 106 cases followed by melena in 77 (39%) and in both (9%).

In our study most common gastrointestinal findings were various accounting for 33.5% followed by gastric ulcers (16%), esophagitis (14%), antral gastritis (12%), hemorrhagic gastritis (9%), erosive gastritis (4%), pan gastritis (4%), duodenitis (4%), congestive gastropathy (4%), corrosive gastritis (1%), corrosive injury (2%), Mallory-Weiss syndrome (0.5%) respectively.

In our study the incidence of gastritis was 12% which is comparable to other studies done by Sarwari et al (17) and Zia Uddin (13) found to be 13% and 18% respectively.

The majority of cases were due to variceal bleed (33.5%) which may be due to alcohol intake and liver disease in the study group.

Our study found that incidence of variceal bleed was higher as compared to the other studies, which may be due to major risk factors in the study population such as smoking and alcohol.



REFERENCES

1. Kelvin Palmer. Acute upper gastrointestinal haemorrhage, *Br Med Bull*, 2007;83(1):307-24.
2. A. N. Barkun, M. Bardou, E. J. Kuipers et al. International consensus recommendations on the management of patients with nonvariceal upper gastrointestinal bleeding. *Annals of Internal Medicine*, 2010;152(2):101-13
3. Hearnshaw SA, Logan RF, Lowe D, et al. Acute upper gastrointestinal bleeding in the UK: patient characteristics, diagnoses and outcomes in the 2007 UK audit. *Gut* 2011;60:1327-35. [PubMed] [Google Scholar]
4. Kelvin Palmer. Acute upper gastrointestinal haemorrhage, *Br Med Bull*, 2007;83(1):307-24
5. Acosta R.D. Differential diagnosis of upper gastrointestinal bleeding proximal to the ligament of Trietz. *Gastrointest Endosc Clin N Am*. 2011; **21**: 555-566
6. Lee YT, Walmsley RS, Leong RW, Sung JJ, Dieulafoy's lesion. [2] Weston AP, Hiatal hernia with Cameron ulcers and erosions. *Gastrointestinal endoscopy clinics of North America*. 1996 Oct; **1**: 1-10
7. Stanley AJ, Laine L. Management of acute upper gastrointestinal bleeding. *BMJ*. 2019 Mar
8. Cooper AS. Interventions for Preventing Upper Gastrointestinal Bleeding in People Admitted to Intensive Care Units. *Crit Care Nurse*. 2019 Apr; **39**(2):102-103. [PubMed]
9. Hwang JH, Fisher DA, Ben-Menachem T, et al. The role of endoscopy in the management of acute non-variceal upper GI bleeding. *Gastrointest Endosc* 2012; **75**:1132.
10. Laine L, Barkun AN, Saltzman JR, et al. ACG Clinical Guideline: Upper Gastrointestinal and Ulcer Bleeding. *Am J Gastroenterol* 2021; **116**:899.
11. <https://www.uclahealth.org/radiology/ir/gastrointestinal-bleeding>
12. <https://www.medicalnewstoday.com/articles/upper-gi-bleed#summary>
13. Longstreth GF. Epidemiology of hospitalization for acute upper gastrointestinal haemorrhage: a population based study. *Am J Gastroenterol* 1995; **90**:206-210.
14. https://www.emedicinehealth.com/gastrointestinal_bleeding/article_em.htm
15. Wilkins T, Khan N, Nabh A, Schade RR. Diagnosis and management of upper gastrointestinal bleeding. *Am Fam Physician*. 2012; **85**(5):469-76. **PubMed Google Scholar**
16. Enestvedt BK, Gralnek IM, Mattek N, et al. An evaluation of endoscopic indications and findings related to nonvariceal upper-GI hemorrhage in a large multicenter consortium. *Gastrointest Endosc* 2008; **67**:422-9. [Crossref] [PubMed]
17. Barkun A, Sabbah S, Enns R, et al. The Canadian Registry on Nonvariceal Upper Gastrointestinal Bleeding and Endoscopy (RUGBE): Endoscopic hemostasis and proton pump inhibition are associated with improved outcomes in a real-life setting. *Am J Gastroenterol* 2004; **99**:1238-46. [Crossref] [PubMed]
18. <https://bmcgastroenterol.biomedcentral.com/articles/10.1186/s12876-017-0712-8>
19. <https://www.nejm.org/doi/full/10.1056/NEJMoa1912484>
20. <https://ijhcr.com/index.php/ijhcr/article/view/2913/2049>
21. Allan R, Dykes P. A study of the factors influencing mortality rates from gastrointestinal haemorrhage. *QJ Med*. 1976; **45**:533-50. [PubMed]
22. Boley SJ, Sammartano R, Adams A, DiBiase A, Kleinhaus S, Sprayregen S. On the nature and etiology of vascular ectasias of the colon. Degenerative lesions of aging. *Gastroenterology*. 1977; **72**:650-60. [PubMed]
23. Rockall TA, Logan RF, Devlin HB, et al. Incidence of and mortality from acute upper gastrointestinal haemorrhage in the United Kingdom. Steering Committee and members of the National Audit of Acute Upper Gastrointestinal Haemorrhage. *BMJ* 1995; **311**:222-6. [PMC free article] [PubMed] [Google Scholar]
24. de Groot NL, Bosman JH, Siersema PD, et al. Prediction scores in gastrointestinal bleeding: a systematic review and quantitative appraisal. *Endoscopy* 2012; **44**:731-9. [PubMed] [Google Scholar]
25. Pilotto A, Franceschi M, Leandro G, Paris F, Niro V, Longo MG, D'Ambrosio LP, Andriulli A, Di Mario F (2003). "The risk of upper gastrointestinal bleeding in elderly users of aspirin and other non-steroidal anti-inflammatory drugs: the role of



- gastroprotectivedrugs". *Aging Clin Exp Res.* **15** (6): 4949. PMID 14959953.
26. HreinssonJP, KalaitzakisE, Gudmundsson S, BjrnssonES (2013). "Uppergastrointestinal bleeding: incidence, etiologyandoutcomes in a population-based setting". *Scand.J. Gastroenterol.* **48** (4): 43947. doi:10.3109/00365521.2012.763174. PMC 3613943. PMID 23356751.
 27. DriniM (2017). "Pepticulcer disease and non-steroidal anti-inflammatory drugs". *AustPrescr.* **40** (3):9193. doi:10.18773/austprescr.2017.037. PMC 5478398. PMID 28798512.
 28. KavianiMJ, PirastehfarM, Azari A, SaberifirooziiM (2010). "Etiologyand outcome of patients with uppergastrointestinal bleeding: a study from South of Iran". *SaudiJ Gastroenterol.* **16** (4): 2539. doi:10.4103/1319-3767.70608. PMC 2995092. PMID 20871188.
 29. DavidsonAT (1985). "Uppergastrointestinal bleeding: causes and treatment". *JNatl Med Assoc.* **77** (11): 9445. PMC 2571206. PMID 4078920.
 30. van LeerdamME (2008). "Epidemiology of acute uppergastrointestinal bleeding". *Best PractResClin Gastroenterol.* **22** (2): 20924. doi:10.1016/j.bpg.2007.10.011. PMID 18346679.
 31. Morales Uribe CH, Sierra SierraS, HernndezHernndezAM, Arango Durango AF, LpezGA (2011). "Upper gastrointestinal bleeding: risk factors for mortality intwo urban centres in Latin America". *Rev EspEnfermDig.* **103** (1): 204. PMID 21341933.
 32. Rodriguez-HernndezH, Rodriguez-MornM, Gonzlez JL, Jquez-Quintana JO, RodriguezAcosta ED, Sosa-Tinoco E,Guerrero-Romero F (2009). "[Risk factors associated with uppergastrointestinal bleeding and with mortality]". *Rev Med Inst MexSeguro Soc (in Spanish; Castilian).* **47** (2): 17984. PMID 19744387.
 33. CorzoMaldonado MA, Guzmn Rojas P, Bravo ParedesEA, Gallegos Lpez RC, Huerta Mercado-Tenorio J, SurcoOchoa Y, ProchazkaZrateR, PiscocoyaRivera A, Pinto Valdivia J, De losRosSenmacheR (2013)."[Risk factors associated to mortality by upper GI bleeding in patientsfrom a public hospital. A case control study]". *Rev GastroenterolPeru (in Spanish; Castilian).* **33** (3): 2239. PMID 24108375.
 34. Brooks J,Warburton R, Beales IL (2013). "Preventionof upper gastrointestinal haemorrhage: current controversies and clinicalguidance". *TherAdv Chronic Dis.* **4** (5): 20622. doi:10.1177/2040622313492188. PMC 3752180. PMID 23997925.
 35. Kim BS, LiBT, Engel A, Samra JS, Clarke S, Norton ID, Li AE (2014). "Diagnosisof gastrointestinal bleeding: A practical guide frclinicians". *World J GastrointestPathophysiol.* **5** (4):46778. doi:10.4291/wjgp.v5.i4.467. PMC 4231512. PMID 25400991.
 36. StruijkM, Postma DF, van TuylSA, van de ReeMA (2012). "Optimal drug therapyafter aspirin-induced upper gastrointestinal bleeding". *Eur. J.Intern. Med.* **23** (3): 22730. doi:10.1016/j.ejim.2011.10.004. PMID 22385878.
 37. Zhang YS,Li Q, He BS, Liu R, Li ZJ (2015). "Protonpump inhibitors therapy vs H2 receptor antagoniststherapy for upper gastrointestinal bleeding after endoscopy: Ametaanalysis". *World J.Gastroenterol.* **21** (20): 634151. doi:10.3748/wjg.v21.i20.6341. PMC 4445112. PMID 26034370.
 38. GurinA, ModyR,Carter V, AyasC, Patel H, LaschK, Wu E (2016). "Changesin Practice Patterns of Clopidogrel in Combination with Proton Pump Inhibitorsafter an FDA Safety Communication". *PLoSONE.* **11** (1): e0145504. doi:10.1371/journal.pone.0145504. PMC 4699636. PMID 267
 39. <http://www.uptodate.com/contents/approach-to-acute-upper-gastrointestinal-bleeding-inadults>.

Cite this Article: Pavani Tekumalla, Dr. Vamshi Krishna V., Dr. Y. Karunakar Reddy, Roqsar Firdouse (2023). Prospective Study on Upper GI Bleeding. International Journal of Current Science Research and Review, 6(5), 2862-2873